Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

BACKGROUND: De novo combination of lamivudine (Lam) and adefovir (Adv) was not rarely used in clinical practice. However, head-to-head comparisons of entecavir (Etv) monotherapy with this combination in hepatitis B virus (HBV)-related compensated cirrhosis patients are unavailable. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoning, Zhou, Jialing, Xie, Wen, Ding, Huiguo, Ou, Xiaojuan, Chen, Guofeng, Ma, Anlin, Xu, Xiaoyuan, Ma, Hui, Xu, Youqing, Liu, Xiaoqing, Meng, Tongtong, Wang, Lin, Sun, Yameng, Wang, Bingqiong, Kong, Yuanyuan, Ma, Hong, You, Hong, Jia, Jidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448536/
https://www.ncbi.nlm.nih.gov/pubmed/31015765
http://dx.doi.org/10.2147/IDR.S185120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448536/
https://www.ncbi.nlm.nih.gov/pubmed/31015765
http://dx.doi.org/10.2147/IDR.S185120

Ejemplares similares